Quince Therapeutics, Inc. (QNCX)
Nasdaq · Healthcare · Biotechnology
$28.10−3.77%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $28.6M
- 52-week range
- $15.10 – $910.00
- 52-week change
- −92.51%
- EPS (trailing)
- −$214.01
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$84.0M
- Diluted EPS
- −$1.68
- Free cash flow
- −$41.8M
From the company’s annual report on SEC EDGAR.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 38 employees · quincetx.com